RICERCA ITALIANA     

FIRB simili:

• 1 - Modelli di dipendenza: correlati molecolari e funzionali.
• 2 - Meccanismi di vulnerabilita' neuronale: identificazione di nuovi target biologici per lo sviluppo di terapie innovative
• 3 - SVILUPPO ED APPLICAZIONE DI TECNOLOGIE ALTAMENTE INNOVATIVE ED EFFICIENTI PER LA SINTESI DI NUOVE MOLECOLE CON DIMOSTRAZIONE DELLA LORO ATTIVITA' BIOLOGICA SU PROTEINE DI MEMBRANA IMPLICATE NEL DANNO CEREBRALE.
• 4 - Sviluppo di molecole innovative in grado di curare malattie neurodegenerative e neuroinfiammatorie.
• 5 - Riconoscimento molecolare e funzionalità cellulare
• 6 - Plasticità sinaptica e riparazione del danno cerebrale
• 7 - Interazioni funzionali tra proteine delle sinapsi: fisiopatologia e potenziali indicazioni terapeutiche
• 8 - Sviluppo di Tecnologie Avanzate per lo Studio della Proteomica Differenziale del Segnale (Segnalo-Proteomica)
• 9 - Modelli transgenici per malattie ad eziologia complessa
• 10 - Geni murini, fenotipi e malattie umane - MousePHD

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • FARMACOLOGIA
• Area scientifico disciplinare: Scienze mediche
  • NEUROLOGIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Toscana

Bibliografia

Alvord, E.C. Jr.; Forno, L.S. Pathology. In: Koller, W.C., ed. Handbook of Parkinson's disease, 2nd edit. New York: Marcel Dekker; 1992: 255-284

Baumgarten, H. G.; Zimmermann, B. Cellular and subcellular targets of neurotoxins: the concept of selective vulnerability. In: Herken, H.; Hucho, F., eds. Selective Neurotoxicity. Berlin: Springer-Verlag; 1992:1-27.

Beal, M. F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31:119-130; 1992.


Carboni, S.; Melis, F.; Pani, L.; Hadgiconstantinou, M.; Rossetti, Z. Non-competitive NMDA receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by MPP+. Neurosci. Lett. 117:129-133; 1990.

Carlsson, M.; Carlsson, A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-Implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:272-277; 1990.

Cha, J. H.; Dure, L. S. I. V.; Sakurai, S. Y.; Penney, J. B.; Young, A. B. 2,4,5, trihydroxyphenylalanine (6-hydroxy-DOPA) displaces (3H) AMPA binding in rat striatum. Neurosci. Lett. 132:55-58; 1991.


Chiueh, C. C.; Huang, S. J. MPP+ enhances potassium-evoked striatal dopamine release through a omega-conotoxin-insensitive, tetrodotoxin- and nimodipine-sensitive calcium-dependent mechanism. Ann. N.Y. Acad. Sci. 635:393-396; 1991.
Choi, D. W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:623-634; 1988.

Cotman, C. W.; Monaghan, D. T.; Ottersen, O. P.; Storm-Mathisen, J. Anatomical organization of excitatory amino acid receptors and their pathways. Trends Neurosci. 10:273-280; 1987.

Fahn, S.; Cohen, G. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann. Neurol. 32:804-812; 1992.

Fonnum, F. Glutamate: a neurotransmitter in the mammalian brain. J. Neurochem. 42:1-11; 1984.

Fornai, F.; Vaglini, F.; Maggio, R.; Bonuccelli, U.; Corsini, G. U. Excitatory amino acids and MPTP toxicity. Adv. Neurol. 69:167-176; 1996.

Kass, I. S.; Lipton, P. Mechanisms involved in irreversible anoxic damage to the in vitro rat hippocampal slice. J. Physiol. 332:459-472; 1982.

Lafon-Cazal, M.; Pietri, S.; Culcasi, M.; Bockaert, J. NMDA-dependent superoxide production and neurotoxicity. Nature. 364:535-537; 1993.

Lange, K. W.; Loschmann, P. A.; Sofic, E.; Burg, M.; Horowski, R.; Kalveram, K. T.; Wachtel, H.; Riederer, P. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn Schmiedeberg's Arch. Pharmacol. 348:586-592; 1993.


Marshall, J. F.; O'Dell, S. J.; Weihmuller, F. B. Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity. J. Neural Transm. (Gen. Sec.) 91:241-254; 1993.


Mereu, G.; Costa, E.; Armstrong, D. M.; Vicini, S. Glutamate receptors subtypes mediate excitatory synaptic currents of dopamine neurons in midbrain slices. J Neurosci. 11:1359-1366; 1991.

Montastruc, J. L.; Rascol, O.; Senard, J. M.; Rascol, A. A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. J. Neurol. Neurosurg. Psych. 55:630-631; 1992.

Nash, J. F.; Yamamoto, B. K. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 581:237-243; 1992.

Nicholls, D.; Atwell, D. The release and uptake of excitatory amino acids. Trends Pharmacol. Sci. 11:462-468; 1990.

O'Dell, S. J.; Weihmuller, F. B.; Marshall, J. F. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res. 564:256-260; 1991.

O'Dell, S. J.; Weihmuller, F. B.; Marshall, J. F. MK-801 prevents methamphetamine-induced striatal dopamine damage and reduces extracellular dopamine overflow. In: Neurotoxins and neurodegenerative disease Ann. N.Y. Acad. Sci. 648:317-319; 1992.

Olney, J. W.; de Gubareff, T. Glutamate neurotoxicity and Huntington's chorea. Nature. 271:557-559; 1978.

Olney, J. W. Excitotoxic mechanisms of neurotoxicity. In: Spencer P. S.; Shaumberg, H. H. eds. Experimental and Clinical Neurotoxicology. Baltimore: Williams and Wilkins; 1980:272-294.

Olney, J. W. Excitotoxic amino acids and neuropsychiatric disorders. Ann. Rev. Pharmacol. Toxicol. 30:47-71; 1990.

Olney, J. W.; Zorumsky, C. F.; Stewart, G. R.; Price, M. T.; Wang, G.; Labruyere, J. Excitotoxicity of l-DOPA and 6-OH-DOPA: implications for Parkinson's and Huntington's disease. Exp. Neurol. 108:269-272; 1990.

Ossowska, K. The role of excitatory amino acids in experimental models of Parkinson's disease. J. Neural. Transm. (P-D Sect). 8:39-71; 1994 .

Overton, P.; Clark, D. N-methyl-D-aspartate increases the excitability of nigrostriatal dopamine terminals. Eut. J. Pharmacol. 201:117-120; 1991.

Piallat, B.; Bernazzouz, A.; Bressand, K.; Vercueil, L.; Benabid, A. L. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection. Soc. Neurosci. Abs. 230:5; 1995.


Rollema, H.; Damsma, G.; Horn, A. S.; De Vries, J. B.; Westerink, B. H. Brain dialysis in conscious rats reveals an instantaneous massive release of striatal dopamine in response to MPP+. Eur. J. PHarmacol. 126:345-346; 1986.

Rothman, S. M. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J. Neurosci. 4:1884-1891; 1984.

Sachs, C.; Jonsson, G. Mechanism of action of 6-hydroxydopamine. Biochem. Pharmacol. 24:1-8; 1975.


Sloviter, R. S. "Epileptic" brain damage in rats induced by sustained elctrical stimulation of the perforant path. I Acute electrophysiological and light microscopic studies. Brain Res. Bull. 10:675-697; 1983.

Sloviter, R. S.; Sollas, A. L.; Dean, E.; Dichter, M. A. Immunocytochemical localization of 65 and 67kDa glutamic acid decarboxylase (GAD) and GABA-like immunoreactivities in the rat hippocampal formation; GAD 67 and GABA are present in normal dentate granule cells and are rapidly induced by afferent stimulation, kainic acid or pilocarpine. Soc. Neurosci. Abs. 771:2; 1995.

Sonsalla, P. K.; Nicklas, W. J.; Heikkila, R. E. Role for excitatory amino acids in metamphetamine-induced nigrostriatal dopaminergic toxicity. Science. 243:398-400; 1989.

Sonsalla, P. K.; Nicklas, W. J. MPTP and animal models of Parkinson's disease. In Koller, W. C., ed. Handbook of Parkinson's disease. 2nd ed. New York: Marcel Dekker; 1992:319-340.

Sonsalla, P. K.; Riordan, D. E.; Heikkila, R. E. Competitive and non-competitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther. 256:506-512; 1991.

Sonsalla, P. K.; Giovanni, A.; Sieber, B.-A.; Delle Donne, K.; Manzino, L. Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine. In: Neurotoxins and neurodegenerative disease Ann. NY Acad. Sci. 648:229-238; 1992.

Storey, E.; Hyman, B. T.; Jenkins, B.; Brouillet, E.; Miller, J. M.; Rosen, B. R.; Beal, M. F. 1-methyl-4-phenylpyridinium produces excitotoxic lesion in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem. 58:1975-1978; 1992.

Tanner, C. M. Epidemiological clues to the cause of Parkinson's disease. In: Fahn, S.; Marsden, C. D. eds. Movement Disorders, vol. 3. Oxford: Butterworth-Heinemann; 1994:124-146.

Taylor, J. R.; Elsworth, J. D.; Roth, R. H.; Sladek, J. R.; Redmond, D. E. Behavioral effects of MPTP administration in the Vervet monkey: a primate model of Parkinson's disease. In: Woodruff, M. L.; Nonneman, A. J., eds. Toxin-induced models of neurological disorders New York: Plenum Press; 1994:139-174.

Turski, L.; Bressler, K.; Rettig, K. J.; Loshmann, P. A.; Wachtel, H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349:414-418; 1991.

Parole Chiave

glutammato; Malattia di Parkinson; recettori metabotropi; neurodegenerazione; disturbi del movimento